Search Results - "Flaherty, KT"

New molecular targets in melanoma by Flaherty, Keith T

“…Metastatic melanoma remains a disease with few therapeutic options and no regimen that prolongs survival. Peptide and whole-cell vaccines that use cell surface…”
Get full text

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

“…Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and…”
Get full text

Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma by Flaherty, Keith T

“…For three decades, clinical trials with chemotherapy in melanoma have failed to show superiority of any one regimen over another. Dacarbazine remains the only…”
Get full text

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases by Smalley, Keiran S M, Haass, Nikolas K, Brafford, Patricia A, Lioni, Mercedes, Flaherty, Keith T, Herlyn, Meenhard

“…Although >66% of melanomas harbor activating mutations in BRAF and exhibit constitutive activity in the mitogen-activated protein kinase/extracellular…”
Get full text

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas by Smalley, Keiran S M, Lioni, Mercedes, Dalla Palma, Maurizia, Xiao, Min, Desai, Brijal, Egyhazi, Suzanne, Hansson, Johan, Wu, Hong, King, Alastair J, Van Belle, Patricia, Elder, David E, Flaherty, Keith T, Herlyn, Meenhard, Nathanson, Katherine L

“…Recent studies have shown that there is a considerable heterogeneity in the response of melanoma cell lines to MEK and BRAF inhibitors. In the current study,…”
Get full text

Mechanisms of Hypertension Associated With BAY 43-9006 by VERONESE, Maria Luisa, MOSENKIS, Ari, FLAHERTY, Keith T, GALLAGHER, Maryann, STEVENSON, James P, TOWNSEND, Raymond R, O'DWYER, Peter J

“…BAY 43-9006 (sorafenib) is an inhibitor of Raf kinase, the vascular endothelial growth factor (VEGF) receptor-2, and angiogenesis in tumor xenografts. The…”
Get full text

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalá, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

Get full text

PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms by Trusheim, MR, Shrier, AA, Antonijevic, Z, Beckman, RA, Campbell, RK, Chen, C, Flaherty, KT, Loewy, J, Lacombe, D, Madhavan, S, Selker, HP, Esserman, LJ

“…Adaptive, seamless, multisponsor, multitherapy clinical trial designs executed as large scale platforms, could create superior evidence more efficiently than…”
Get full text

A Prospective Study of Body Mass Index, Hypertension, and Smoking and the Risk of Renal Cell Carcinoma (United States) by Flaherty, Keith T., Fuchs, Charles S., Colditz, Graham A., Stampfer, Meir J., Speizer, Frank E., Willett, Walter C., Curhan, Gary C.

“…Objective: We prospectively investigated the independent association of hypertension, thiazide use, body mass index, weight change, and smoking with the risk…”
Get full text

Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin by BILENKER, Joshua H, FLAHERTY, Keith T, SCHNALL, Mitchell, O'DWYER, Peter J, ROSEN, Mark, DAVIS, Lisa, GALLAGHER, Maryann, STEVENSON, James P, WEIJING SUN, VAUGHN, David, GIANTONIO, Bruce, ZIMMER, Ross

“…Purpose: Preclinical evidence of synergy led to a phase I trial employing combretastatin A-4 phosphate (CA4P), a novel tubulin-binding antivascular drug, in…”
Get full text

PCN110 A RETROSPECTIVE CLAIMS DATABASE COMPARISON OF SORAFENIB AND SUNITINIB DOSING PATTERNS IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) by Keefe, S, Moyneur, E, Barghout, V, Flaherty, KT

Get full text

A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i) by Gasal, E, Fernandez, AMA, Ascierto, PA, Atkinson, V, Dummer, R, Flaherty, KT, Grob, JJ, Hansson, J, Hassel, J, Larkin, J, Lebbe, C, Long, GV, Lorigan, P, Miller, W, Nathan, P, Ribas, A, Robert, C, Schadendorf, D, Tawbi, H, Upalawanna, A

Get full text

Antisense therapeutics: lessons from early clinical trials by Flaherty, Keith T, Stevenson, James P, O'Dwyer, Peter J

“…The authors review the early clinical experience with antisense oligodeoxynucleotides, documenting their limited toxicity profile and initial reports of…”
Get full text

Innovations and Challenges in Melanoma: Summary Statement from the First Cambridge Conference by Atkins, Michael B, Elder, David E, Essner, Richard, Flaherty, Keith T, Gajewski, Thomas F, Haluska, Frank G, Hwu, Patrick, Keilholz, Ulrich, Kirkwood, John M, Mier, James W, Ross, Merrick I, Slingluff, Craig L, Sondak, Vernon K, Sosman, Jeffrey A, Weinstock, Martin A, King, Laura

“…Innovations and Challenges in Melanoma, chaired by Michael Atkins and cochaired by Ulrich Keilholz, John Kirkwood, and Jeffrey Sosman, was held July 15 to 16,…”
Get full text

A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine by FLAHERTY, Keith T, STEVENSON, James P, REDLINGER, Maryann, ALGAZY, Kenneth M, GIANTONIO, Bruce, O'DWYER, Peter J

“…To develop a combination regimen for clinical testing, we performed a dose escalation study of ZD0473 in combination with gemcitabine. ZD0473 is a novel…”
Get full text

Phase I study of weekly liposome-encapsulated doxorubicin in patients with advanced, androgen-independent prostate cancer by Flaherty, Keith T, Malkowicz, S Bruce, Vaughn, David J

“…We performed a phase I study to evaluate the tolerability and activity of liposome-encapsulated doxorubicin (LED) given intravenously on a weekly basis in…”
Get full text

Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer by Flaherty, Keith T., Stevenson, James P., Gallagher, Maryann, Giantonio, Bruce, Algazy, Kenneth M., Sun, Weijing, Haller, Daniel G., O'Dwyer, Peter J.

“…BACKGROUND The authors performed a dose escalation study of cisplatin and the novel deoxycytidine analog, tezacitabine, to determine the maximum tolerated dose…”
Get full text

Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies by BILENKER, Joshua H, STEVENSON, James P, FLAHERTY, Keith T, ALGAZY, Kenneth, MCLAUGHLIN, Kathy, HALLER, Daniel G, GIANTONIO, Bruce J, KOEHLER, M, GARCIA-VARGAS, J. E, O'DWYER, Peter J

“…To determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of ZD9331 in combination with cisplatin in patients with refractory solid tumors…”
Get full text

Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy by FLAHERTY, Keith T, STEVENSON, James P, HAHN, Stephen M, REDLINGER, Maryann, O'DWYER, Peter J

“…We performed a phase I trial of carboplatin and paclitaxel in combination with gemcitabine in order to determine the tolerability of this triplet. Enrolled in…”
Get full text

Persistent corneal defect caused by Listeria monocytogenes by Eiferman, R A, Flaherty, K T, Rivard, A K

Get more information